This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Spero Therapeutics, Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Ching-Kuo Jim Chow: Innovator in Pharmaceutical Formulations
Introduction
Ching-Kuo Jim Chow is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the formulation of medications. His innovative work has led to the development of a unique tablet formulation that addresses critical medical needs.
Latest Patents
Chow holds a patent for a high dosage tebipenem pivoxil tablet formulation. This patent describes a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w/w) tebipenem pivoxil HBr, with certain embodiments exceeding 80% (w/w). The formulation includes a tablet core that consists of at least 70% w/w tebipenem pivoxil HBr, 5-25% w/w of a diluent, 0.5 to 5% w/w of a glidant, 0.5 to 5% w/w of a lubricant, and optionally 0.5 to 5% w/w of a disintegrant. This innovative formulation provides methods for treating patients with bacterial infections, including complicated urinary tract infections (cUTI), acute and chronic pyelonephritis, upper or lower respiratory infections, and bacteremia.
Career Highlights
Chow is currently associated with Spero Therapeutics, Inc., where he continues to advance his research and development efforts. His work is pivotal in creating effective treatments that can significantly improve patient outcomes.
Collaborations
Chow collaborates with various professionals in the field, including his coworker Akash Jain, who contributes to the innovative projects at Spero Therapeutics, Inc.
Conclusion
Ching-Kuo Jim Chow's contributions to pharmaceutical formulations exemplify the impact of innovation in medicine. His patent for the tebipenem pivoxil tablet formulation showcases his commitment to addressing critical health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile